Contents
Market Overview
North Macedonia has become one of Europe’s leading medical cannabis production and export hubs, despite having limited domestic patient access. The country legalised both the cultivation and manufacture of medical cannabis in 2016, establishing one of the earliest comprehensive regulatory frameworks in the region.
Since legalisation, North Macedonia has issued 66 cultivation and production licences (as of 2022), though only a portion of these companies have successfully achieved commercial output or export certification. A growing number of operators have since obtained EU-GMP accreditation, positioning the country as a strategic production base for the European medical cannabis supply chain.
While the export-oriented industry continues to expand, domestic patient access remains minimal, reflecting regulatory and clinical conservatism within the healthcare system.
Regulatory Framework
The Law on Control of Narcotic Drugs and Psychotropic Substances (2016) governs medical cannabis cultivation, production, and use in North Macedonia. The framework allows for:
- Licensed cultivation, processing, and manufacturing of cannabis for medical and scientific purposes.
- Export of cannabis extracts and oil-based products, but not dried flower, which remains prohibited for international trade.
- Strict state oversight of all activities through the Ministry of Health, the Agency for Medicines and Medical Devices (MALMED), and the Ministry of Interior.
Licensing and Compliance:
- Cultivation and processing require separate permits.
- All operators must meet Good Agricultural and Collection Practices (GACP) and Good Manufacturing Practice (GMP) standards.
- Exports are limited to countries that have legal medical cannabis frameworks and reciprocal import permissions.
In recent years, North Macedonia has undertaken legislative revisions aimed at harmonising its framework with EU pharmaceutical standards, with a focus on quality assurance and export competitiveness.
Industry and Export Landscape
North Macedonia’s cannabis industry is predominantly export-oriented, supported by favourable climatic conditions, low production costs, and a skilled agricultural workforce.
Key Industry Characteristics:
- As of 2022, 66 companies held licences for medical cannabis production.
- Only 10–15 companies are believed to be commercially active exporters, due to the financial and technical demands of achieving EU-GMP certification.
- Extracts and oil-based products dominate exports, as flower exports remain restricted.
Export Markets:
- Primary export destinations include Germany, Poland, and the Czech Republic, with smaller volumes shipped to Israel, Australia, and the UK.
- Export growth has been supported by foreign investment partnerships, particularly with Canadian, Israeli, and German firms.
North Macedonia’s role as a low-cost, high-capacity producer has made it a preferred source for European pharmaceutical intermediates and extracts.
Patient Access
While medical cannabis production and export are well-established, domestic patient access is extremely limited. The same 2016 legislation that legalised cultivation also permitted medical use under strict conditions, but implementation has been slow and highly restrictive.
Who Can Prescribe?
Only government-approved doctors with recognised specialisations in certain diseases are permitted to prescribe medical cannabis.
Approved Indications:
- Multiple sclerosis
- Epilepsy
- HIV/AIDS
- Certain forms of cancer
Prescription and Access Barriers:
- Patients must receive approval from a specialist physician authorised by the Ministry of Health.
- Very few pharmacies are equipped to dispense cannabis-based medicines.
- The system lacks public reimbursement, with patients paying the full cost of treatment.
As a result, domestic patient numbers remain exceptionally low, and medical cannabis use in North Macedonia is primarily pharmaceutical and export-focused, rather than patient-driven.
Outlook
North Macedonia’s medical cannabis framework illustrates a dual reality: an internationally competitive production industry contrasted with limited local therapeutic application.
The country’s export-oriented ecosystem, bolstered by growing numbers of EU-GMP-certified producers, positions it as a key player in Europe’s medical cannabis supply chain, particularly for bulk extracts and intermediate products.
Future growth depends on:
- Continued regulatory alignment with EU standards.
- Expansion of export markets and product diversity.
- Possible reforms to improve domestic patient access.
If local access pathways are modernised, North Macedonia could transition from a purely export market to a comprehensive medical cannabis system encompassing both domestic treatment and global supply.
